Endothelin-1 in humans is increased by oxygen-derived radicals ex vivo and in vivo

Journal of Investigative Medicine

Volumn 55, Issue 6, 2007, Pages 306-314

  Knappe, Dorit ^a   Sill, Bjoern ^a   Tharun, Bjoern ^a   Koester, Ralf ^a   Baldus, Stephan ^a   Muenzel, Thomas ^b   Meinertz, Thomas ^a   Kähler, Jan ^a,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

Angiotensin II; Endothelin 1; Oxygen derived radicals; Oxypurinol

Indexed keywords

ANGIOTENSIN II; CATALASE; ENDOTHELIN 1; OXIPURINOL; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERNAL MAMMARY ARTERY; MALE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 36749033838     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2007.00013     Document Type: Article

References (33)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
2. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
3. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
4. Zeiher AM. Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon? Lancet 1996;348 Suppl 1:s10-2.
5. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991;83: 13-25.
6. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.
7. Alexander BT, Cockrell KL, Rinewalt AN, et al. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 2001;280:R1388-92.
8. Ballew JR, Fink GD. Role of ET(A) receptors in experimental ANG II-induced hypertension in rats. Am J Physiol Regul Integr Comp Physiol 2001;281:R150-4.
9. Barton M, Shaw S, d'Uscio LV, et al. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997;238:861-5.
10. Barton M, Shaw S, d'Uscio LV, et al. Differential modulation of the renal and myocardial endothelin system by angiotensin II in vivo. Effects of chronic selective ETA receptor blockade. J Cardiovasc Pharmacol 1998;31 Suppl 1:S265-8.
11. Kaehler J, Mendel S, Weckmueller J, et al. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol 2000;32:1429-37.
12. Busse R, Fleming I, Hecker M. Signal transduction in endothelium- dependent vasodilatation. Eur Heart J 1993;14 Suppl I:2-9.
13. Guyton KZ, Gorospe M, Wang X, et al. Age-related changes in activation of mitogen-activated protein kinase cascades by oxidative stress. J Investig Dermatol Symp Proc 1998;3:23-7.
14. Love GP, Keenan AK. Cytotoxicity-associated effects of reactive oxygen species on endothelin-1 secretion by pulmonary endothelial cells. Free Radic Biol Med 1998; 24:1437-45.
15. Hughes AK, Stricklett PK, Padilla E, Kohan DE. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int 1996;49:181-9.
16. Michael JR, Markewitz BA, Kohan DE. Oxidant stress regulates basal endothelin-1 production by cultured rat pulmonary endothelial cells. Am J Physiol 1997;273:L768-74.
17. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003;107:1383-9.
18. Cardillo C, Kilcoyne CM, Cannon RO III, et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997;30:57-63.
19. Carpenter TC, Stenmark KR. Endothelin receptor blockade decreases lung water in young rats exposed to viral infection and hypoxia. Am J Physiol Lung Cell Mol Physiol 2000;279:L547-54.
20. Baldus S, Koester R, Chumley P, et al. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med 2005;39:1184-90.
21. Kaehler J, Sill B, Koester R, et al. Endothelin-1 mRNA and protein in vascular wall cells is increased by reactive oxygen species. Clin Sci (Lond) 2002;103 Suppl 48:176S-8S.
22. Kaehler J, Ewert A, Weckmueller J, et al. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol 2001;38:49-57.
23. Miller FJ, Jr, Gutterman DD, Rios CD, et al. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 1998;82:1298-305.
24. Hojo Y, Ikeda U, Katsuki T, et al. Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty. Catheter Cardiovasc Interv 2000;51:42-9.
25. Davlouros PA, Simeonidou E, Tsakas S, et al. Release of endothelin-1 from human endocardium after radiofrequency catheter ablation and coronary angioplasty: comparative results. Int J Cardiol 2005;102:187-93.
26. Taylor AJ, Bobik A, Richards M, et al. Myocardial endothelin-1 release and indices of inflammation during angioplasty for acute myocardial infarction and stable coronary artery disease. Am Heart J 2004;148:e10.
27. Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation 2002;9:161-75.
28. White CR, Darley-Usmar V, Bemngton WR, et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A 1996;93:8745-9.
29. Sobey CG, Dalipram RA, Dusting GJ, Woodman OL. Impaired endothelium-dependent relaxation of dog coronary arteries after myocardial ischaemia and reperfusion: prevention by amlodipine, propranolol and allopurinol. Br J Pharmacol 1992;105:557-62.
30. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003;107:416-21.
31. Geng Z, Rong Y, Lau BH. S-allyl cysteine inhibits activation of nuclear factor kappa B in human T cells. Free Radic Biol Med 1997;23:345-50.
32. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481-90.
33. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.